Agenus presents clinical data demonstrating durable responses of botensilimab/balstilimab combination in metastatic microsatellite stable colorectal cancer at asco gi
Lexington, mass., jan. 23, 2023 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced clinical data from the mss crc (microsatellite stable colorectal cancer) 70 patient cohort of a phase 1b study of botensilimab (multifunctional fc-enhanced anti-ctla-4) in combination with balstilimab (anti-pd-1) in patients with chemotherapy and/or immunotherapy-resistant tumors. the larger dataset continues to demonstrate that this combination offers superior efficacy and durability compared to what has been reported for standard of care and other investigational therapies in third line metastatic mss crc. the data were presented in the opening late-breaking oral session at the american society of clinical oncology – gastrointestinal cancers symposium (asco gi) in san francisco, ca on saturday jan 21 2023.
AGEN Ratings Summary
AGEN Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission